Impact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia.
Moritz PlatenSteffen FlessaStefan TeipelAnika RädkeAnnelie ScharfWiebke MohrMaresa BuchholzWolfgang HoffmannBernhard MichalowskyPublished in: Alzheimer's & dementia : the journal of the Alzheimer's Association (2023)
Over 24 months, more than every second patient received low-value medications (Lvm). Lvm negatively impact physical, psychological, and financial outcomes. Appropriate measures are needed to change prescription behaviors.